Sugi Predict

Sugi Predict / Compounds / SCHEMBL30980620

SCHEMBL30980620

SCHEMBL30980620

CC(=O)N[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1CCCOCCOCCNC(=O)NCCCC(CCCNC(=O)NCCOCCOCCC[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1NC(C)=O)(CCCNC(=O)NCCOCCOCCC[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1NC(C)=O)NC(=O)OCc1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ HRAS P01112 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ HEXA P06865 1/20 0.36
▸ LGALS8 O00214 1/20 0.34
▸ OGA O60502 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ MMP12 P39900 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30980659 0.96 LMNA (0.41) HRASLMNASMN1; SMN2HEXA
SCHEMBL30980664 0.91 LMNA (0.41) HRASLMNASMN1; SMN2HEXA
SCHEMBL31078937 0.91 HRAS (0.38) HRASLMNASMN1; SMN2HEXAOGA
SCHEMBL30980607 0.87 MDK (0.40) HRASLMNASMN1; SMN2HEXALGALS8
SCHEMBL30980574 0.84 HRAS (0.37) HRASLMNASMN1; SMN2OGA
SCHEMBL30980775 0.82 MAPK1 (0.38) SMN1; SMN2LGALS8OGA
SCHEMBL30980709 0.80 MAPK1 (0.41) SMN1; SMN2LGALS8OGA
SCHEMBL30980624 0.77 MAPK1 (0.52) HRASLMNASMN1; SMN2LGALS8POLB
SCHEMBL30980649 0.77 MAPK1 (0.43) SMN1; SMN2LGALS8
SCHEMBL30980642 0.76 MAPK1 (0.43) SMN1; SMN2LGALS8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4651901-A1 CYCLING LYSOSOMAL TARGETING ANTIBODY CONJUGATES Lycia Therapeutics, Inc. (US) 2025-11-26 — — EP disclosed
EP-4651902-A2 ASGPR BINDING COMPOUNDS AND CONJUGATES Lycia Therapeutics, Inc. (US) 2025-11-26 — — EP disclosed
WO-2025035040-A1 LYSOSOMAL TARGETING BIFUNCTIONAL MOLECULES FOR DEGRADATION OF MUSCLE-SPECIFIC KINASE AUTOANTIBODIES LYCIA THERAPEUTICS, INC. (US) 2025-02-13 — — WO disclosed
WO-2024155747-A2 ASGPR BINDING COMPOUNDS AND CONJUGATES LYCIA THERAPEUTICS, INC. (US) 2024-07-25 — — WO disclosed
Send feedback